

CITRASATE[™] CONCENTRATES

CITRIC ACID CONCENTRATE WITH A REDUCED AMOUNT OF ACETIC ACID

Manufactured in Germany





Citrasate[™] Concentrates

CITRIC ACID CONCENTRATE WITH A REDUCED AMOUNT OF ACETIC ACID

Citrasate is an acid concentrate for dialysis that contains 0.8 mmol/l of citric acid and 0.3 mmol/l of acetic acid, instead of the traditional 3 mmol/l of acetic acid contained in standard acid concentrates.

The use of citrate-based dialysis is beneficial for most patients but is suggested specially for patients with hemodynamic instability (cardiovascular diseases such as arrythmias), with higher inflammation, and fragile patients with nutritional problems.^{1, 2}

The anticoagulant properties of citric acid, combined with a lower volume of acetic acid, improve the biocompatibility, reduce hypotension, and improve dialysis adequacy while reducing the use of heparin.³⁻⁵



Benefits of the citrate-based dialysate:

- Higher biocompatibility and reduction of inflammation
 - Improves inflammation by reducing IL-6 and reducing to 3-fold lower CRP levels^{6,7-9}
 - Decreases eosinophils (higher biocompatibilty)¹⁰
- Reduces intra-dialytic hypotension
 - Reduction of 23% in intra-dialytic hypotension¹⁰
- Reduces heparin use
 - Heparin can be reduced by up to 50%¹¹
- Higher survival
 - Increases the long-term survival of patients by up to 33%.²
- Correction of acidosis
 - Normalizes the acidemia in patients and decreases the post-HD alkalemia.^{10,12}
- Improves nutritional state
 - 7% higher lean mass index (LTI)¹⁰

Electrolyte composition of the ready-to-use dialysis fluid

with dilution 1+44

1 liter of acid concentrate 4xx mixed with 1,775 liters of bicarbonate concentrate 8.4% and 42,225 liters of purified water generates 45 liters of ready-to-use dialysis solution.

Citrasate type	Na+	K+	Ca++	Mg++	Cl-	Acetate	Glucose	Citric
461	139.75	2	1.25	0.5	105.5	0.3	1	0.8
460	139.75	2	1.5	0.5	106	0.3	1	0.8
443	139.75	2	1.5	0.75	106.5	0.3	1	0.8
467	139.75	2	1.65	0.5	106.3	0.3	1	0.8
468	139.75	2	1.75	0.5	106.5	0.3	1	0.8
450	139.75	2	1.75	0.75	107	0.3	1	0.8
462	139.75	3	1.25	0.5	106.5	0.3	1	0.8
463	139.75	3	1.5	0.5	107	0.3	1	0.8
444	139.75	3	1.5	0.75	107.5	0.3	1	0.8
486	139.75	3	1.65	0.5	107.3	0.3	1	0.8
470	139.75	3	1.75	0.5	107.5	0.3	1	0.8
473	139.75	3	1.75	0.75	108	0.3	1	0.8
492	139.75	4	1.5	0.5	108	0.3	1	0.8

From single use to large filling volume packaging, our complete range of packaging offers you the flexibility to choose the format and filling volume which best fits your center's needs, procedure, setup, and storage size.

Bag

Negligible storage space after use Canister • Easy connection • Stand-alone packaging Politainer • Easy connection • Reduced storage space after use CE 279 Stand-alone packaging

Packaging details

	Volume (L)	Reference code	Boxes per pallet	Units per box	Pallet layers	Units per pallet	Pallet type
Page	3.8	CS-xxx-38B-24	40	3	4	120	Euro
Days	4.5	CS-xxx-45B-24	50	2	5	100	Euro
Bags - Big boxes	3.8	CS-xxx-38B-44	4	40	2	160	Euro
	4.5	CS-xxx-45B-44	4	34	2	136	Euro
Politainers 4.5		CS-xxx-45P-18	60	2	6	120	Euro
Politainers - Big boxes	4.5	CS-xxx-45P-28	4	34	2	136	Euro
	4.2	CS-xxx-42C-11	N.A.	N.A.	3	90	Euro
Capistars	5	CS-xxx-50C-11	N.A.	N.A.	3	90	Euro
Camsters	6	CS-xxx-60C-11	N.A.	N.A.	3	90	Euro
	10	CS-xxx-100C-11	N.A.	N.A.	3	60	Euro
Dog in Doy	300	CS-xxx-3000BB-03	N.A.	N.A.	1	1	One way
Day III Dux	500	CS-xxx-5000BB-03	N.A.	N.A.	1	1	Euro

xxx = acid type formula

Not all products are registered and approved for sale in all countries or regions.

Other acid types and packaging units may be available on request.

Please contact your Nipro representative for product availability, order quantities, and information.

Shelf life

35 months

Bag in box

• The most environment-friendly solution

Ø

• Reduced acid concentrate waste

References:

- 1. Matsuyama K, et al. Acetate-free blood purification can impact improved nutritional status in hemodialysis patients. J Artif Organs. 2011
- 2. Pérez-García R, et al. Hypomagnesaemia in haemodialysis is associated with increased mortality risk: its relationship with dialysis fluid. Nefrologia [Engl Ed]. 2020
- 3. Ahrenholz P et al. Heparin reduction and improved compatibility using citrate enriched dialysate. EDTA Congress, Paris 2012, Abstract and poster FP 434 BIOCOMPATIBLE Reduce heparin
- 4. Kossmann RJ et al. Fifty-five percent heparin reduction is safe with Citrasate dialysate in chronic dialysis Patients. ASN Renal week Meeting, 2006, Abstract No. 708 Reduce heparin
- 5. Sands JJ et al. Effects of citrate acid (Citrasate) on Heparin N Requirements and hemodialysis Adequacy: A multicenter, prospective noninferiority trial. Blood. Purif. 2012;33:199-204
- 6. Weiss w, et al. SP681, Decrease of inflammation and bleeding times in chronic dialysis patients by long-term use of citrate-enriched dialysate. nephrology dialysis transplantation. 2017
- 7. de Mutsert R, et al. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant. 2008
- 8. Pizzarelli F, et al. Citrate high volume on-line hemodiafiltration modulates serum Interleukin-6 and Klotho levels: the multicenter randomized controlled study "Hephaestus". J Nephrol. 2021
- 9. Paim BA, et al. Oxidative stress in hypercholesterolemic LDL (low-density lipoprotein) receptor knockout mice is associated with low content of mitochondrial NADP-linked substrates and is partially reversed by citrate replacement. Free Radic Biol Med. 2008
- 10. de Sequera P, et al. Advantages of the use of citrate over acetate as a stabilizer in hemodialysis fluid: A randomized ABC-treat study. Nefrologia (Engl Ed). 2021
- 11. Roland E. Winkler PA, Wolfgang Paetow, Grit Waitz and Hartmut Wolf. Reduction of Heparin and Oxidative Potential by Means of Citrasate™ in High-Flux Dialysis (HFD) and Online Hemodiafiltration (olHDF) in Pre and Postdilution. https://wwwintechopencom/chapters/43095. 2012
- 12. Panichi V, et al. Post-dilution on line haemodiafiltration with citrate dialysate: first clinical experience in chronic dialysis patients. Scientific World Journal. 2013

Nipro Renal Care is part of Nipro Corporation Japan, a leading global healthcare company established in 1954. With over 35,000 employees worldwide, Nipro serves the Medical Device, Pharmaceutical, and Pharmaceutical Packaging industries.

Nipro Renal Care is a global market leader with over 6 decades providing renal solutions for dialysis and dialysis-related treatment. We specialize in developing dialysis machines, water treatment systems, and a comprehensive portfolio of disposable medical equipment.

In order to address the needs of patients, healthcare professionals, and procurement managers alike, Nipro Renal Care is driven by innovation and patient safety to offer the highest quality products that optimize time, effort, and costs.

LIVE LONGER. LIVE BETTER.



www.nipro-group.com/en-en/our-company/our-locations

Please contact your local representative for more information.





Nipro Medical Europe : European Headquarters, Blokhuisstraat 42, 2800 Mechelen, Belgium T: +32 (0)15 263 500 | F: +32 (0)15 263 510 | medical@nipro-group.com | www.nipro-group.com